{
    "doi": "https://doi.org/10.1182/blood-2021-147325",
    "article_title": "Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study ",
    "article_date": "November 5, 2021",
    "session_type": "614.Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies",
    "abstract_text": "Blinatumomab (Blina) and inotuzumab (InO) have improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, many patients (pts) relapse after these treatments and little is known on their outcomes after recurrence and re-treatment with subsequent immunotherapy. We hereby describe the clinical characteristics and outcome of 71 pts with R/R B-ALL treated with both Blina and InO in any sequence - Blina/InO or InO/Blina - at different disease recurrences. At diagnosis, the median age was 34 years (15-64) and the male/female ratio was 1.6. Sixteen pts (22%) were Ph+ ALL, 3 (4%) were t(4;11)+ and 9 (13%) carried a complex karyotypes. ECOG PS was 0-1 in 66 pts (93%). At the time of the first immunotherapy, pts had received a median of 2 previous lines of treatment (1-8). All Ph- pts received intensive chemotherapy front-line; Ph+ pts received TKIs and steroids in 13 cases and intensive chemotherapy plus TKIs in 3 cases. Blina was the first salvage treatment (Blino/InO sequence) in 57 pts (80%) and InO (InO/Blina sequence) in 14 (20%). Twenty-seven pts (38%) had underwent a previous allogeneic hematopoietic stem cell transplantation (HSCT). At the start of Blina as first immunotherapy, the median bone marrow (BM) blast count was 40% (0-100%); at the start of InO as first immunotherapy, the median BM blast count was 64% (2-90%). An extramedullary involvement was present in 5 patients (9%) in the Blina/InO group and in 1 patients (7%) in the InO/Blina group. During immunotherapy, the median number of lumbar punctures was 2 (0-9). A median of 2 cycles were administered for both Blina (range 1-9) and Ino (range 1-4). In the Blina/InO group, after Blina a G3/4 toxicity occurred in 15 cases (26%): non-hematologic in 12 cases (21%), neurologic in 6 (8%). Infections occurred in 17 pts (30%). In the InO/Blina group, after InO a G3/4 toxicity occurred in 3 pts (21%), with extra-hematologic toxicity in 2 cases (14%, liver toxicity 1 case). Infections occurred in 4 cases (28%). In the Blina/InO group, after Blina 36 pts (63%) achieved a complete remission (CR), with a negative minimal residual disease (MRD) in 24 (42%) pts; after InO, a CR was re-achieved in 47 pts (82.4%), with 34 (59.6%) being MRD-. In the InO/Blina group, after InO a CR was reached in 13 cases (93%), with 6 pts (42.8%) being MRD-; after Blina, a CR was re-achieved in 6 pts (42.8%), with 3 (21.4%) being MRD-. This salvage immunotherapy strategy represented a bridge to alloHSCT for 26 pts (37%). From the first immunotherapy, in the Blina/InO group, the median overall survival (OS) was 19 months and after InO 6.3 months (OS in MRD- vs MRD+, p ns). Disease free survival (DFS) after Blina was 7.4 months (11.6 vs 2.7 months in MRD- vs MRD+ pts, p .03) and after InO it was 5.4 months (MRD- vs MRD+ pts, p ns). In the InO/Blina group, the median OS was 9.4 months and after Blina 4.6 months (7.5 vs 2.8 months in MRD- vs MRD+ pts, p .02). DFS after InO was 5.1 months (MRD- vs MRD+ pts, p ns) and after Blina it was 1.5 months (8.7 vs 2.5 gg in MRD- vs MRD+ pts, p .02). OS and DFS in MRD- pts after Blina was significantly better, both in the Blina/InO and the InO/Blina groups. With a median follow-up of 16.5 months from the start of immunotherapy and 33.8 months from initial diagnosis, 24 pts (34%) are alive and 16 (22%) are alive in CR. Four patients (6%) died in CR due to veno-occlusive disease during HSCT after InO treatment. Interestingly, OS and DFS from the first immunotherapy was better in pts with a previous alloHSCT (median survival 24.2 vs 13 months, p=.0135). AlloHSCT after second immunotherapy was associated with a better OS and DFS (OS 9.8 and DFS 7.2 months vs 7.8 and 4.4 months, p ns). Our real-life study in R/R B-cell ALL pts with multiple previous lines of treatment demonstrates the feasibility and efficacy of a sequential immunotherapy strategy in terms of MRD response, DFS and OS, and as a bridge to HSCT. SM and PC: equal contributors Disclosures Papayannidis:  Janssen: Honoraria; Astellas: Honoraria; AbbVie: Honoraria; Amgen: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Curti:  Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Chiaretti:  amgen: Consultancy; pfizer: Consultancy; novartis: Consultancy; Incyte: Consultancy. Forghieri:  Jannsen: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Jazz: Honoraria. Bonifacio:  Bristol Myers Squibb: Honoraria; Amgen: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Cerrano:  Janssen: Honoraria; Insight: Honoraria; Jazz: Honoraria. Fracchiolla:  Gilead: Honoraria, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.",
    "author_names": [
        "Mariarita Scium\u00e8",
        "Cristina Papayannidis",
        "Antonio Curti",
        "Antonella Vitale",
        "Sabina Chiaretti",
        "Mario Annunziata",
        "Fabio Giglio",
        "Prassede Salutari",
        "Fabio Forghieri",
        "Davide Lazzarotto",
        "Monia Lunghi",
        "Annalisa Imovilli",
        "Barbara Scappini",
        "Massimiliano Bonifacio",
        "Michelina Dargenio",
        "Carmela Gurrieri",
        "Elisabetta Todisco",
        "Marzia Defina",
        "Maria Ilaria Del Principe",
        "Patrizia Zappasodi",
        "Marco Cerrano",
        "Lidia Santoro",
        "Enrico Barozzi",
        "Pasquale De Roberto",
        "Elisa Buzzatti",
        "Chiara Sartor",
        "Luca Baldini",
        "Robin Foa",
        "Nicola S Fracchiolla"
    ],
    "author_dict_list": [
        {
            "author_name": "Mariarita Scium\u00e8",
            "author_affiliations": [
                "Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Cristina Papayannidis",
            "author_affiliations": [
                "IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli\", Bologna, Italy., Bologna, Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Curti",
            "author_affiliations": [
                "IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli\", Bologna, Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonella Vitale",
            "author_affiliations": [
                "Hematology, Department of Translational and Precision Medicine, Sapienza University, Division of Hematology, Rome, Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sabina Chiaretti",
            "author_affiliations": [
                "Department of Translational and Precision Medicine, Division of Hematology, Rome, Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Annunziata",
            "author_affiliations": [
                "Hematology Unit, Azienda Ospedaliera Cardarelli, Naples, Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabio Giglio",
            "author_affiliations": [
                "Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Prassede Salutari",
            "author_affiliations": [
                "Dipartimento Oncologia Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabio Forghieri",
            "author_affiliations": [
                "Section of Hematology, Department of Surgical and Medical Sciences,, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Davide Lazzarotto",
            "author_affiliations": [
                "Division of Hematology, University Hospital-ASUFC, Udine, Italy"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Monia Lunghi",
            "author_affiliations": [
                "Division of Hematology Department of Translational Medicine, AOU Maggiore della Carit\u00e0, Universit\u00e0 del Piemonte Orientale, Novara, ITA"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Annalisa Imovilli",
            "author_affiliations": [
                "Hematology Unit, Azienda Unit\u00e0 Sanitaria Locale-IRCCS,, Reggio Emilia, Italy"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Scappini",
            "author_affiliations": [
                "Hematology Unit, Department of Experimental and Clinical Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimiliano Bonifacio",
            "author_affiliations": [
                "Department of Medicine, Section of Hematology, University of Verona, Verona, Italy"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michelina Dargenio",
            "author_affiliations": [
                "Hematology and Stem Cell Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy, Lecce, Italy"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carmela Gurrieri",
            "author_affiliations": [
                "Dipartimento Strutturale Aziendale Medicina, University of Padova, Padua, ITA"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elisabetta Todisco",
            "author_affiliations": [
                "Division of Onco-Hematology, European Institute of Oncology IRCCS, Milano, Italy"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marzia Defina",
            "author_affiliations": [
                "Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, ITA"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Ilaria Del Principe",
            "author_affiliations": [
                "Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 degli studi di Roma Tor Vergata, Roma, Italy"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patrizia Zappasodi",
            "author_affiliations": [
                "Department of Hematology Oncology Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Cerrano",
            "author_affiliations": [
                "Division of Hematology, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lidia Santoro",
            "author_affiliations": [
                "Struttura Complessa di Ematologia e Trapianto Emopoietico, A.O. S.G.Moscati., Avellino, ITA"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Enrico Barozzi",
            "author_affiliations": [
                "Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pasquale De Roberto",
            "author_affiliations": [
                "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elisa Buzzatti",
            "author_affiliations": [
                "Ematologia, Dipartimento di Biomedicina e Prevenzione, Tor Vergata University, Rome, Italy"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Chiara Sartor",
            "author_affiliations": [
                "Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luca Baldini",
            "author_affiliations": [
                "UO Ematologia, Fondazione IRCCS C\u00e0 Granda, OM Policlinico, Universit\u00e0 degli Studi, Milan, Italy"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robin Foa",
            "author_affiliations": [
                "Institute of Hematology, University La Sapienza and Hospital Umberto I, Rome, Italy"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola S Fracchiolla",
            "author_affiliations": [
                "Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",
                "Hematology Unit, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, MILANO, Italy"
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-22T21:32:57",
    "is_scraped": "1"
}